Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (Baiyunshan PH) reported stable first-half revenue but weaker earnings, while announcing a cash dividend as it presses on with product launches, overseas expansion and digital upgrades.
Revenue edged up 0.61 % year-on-year to RMB42.09 billion, driven by a 6.03 % rise in Pharmaceutical Commerce to RMB29.94 billion that offset double-digit declines in Modernised Traditional Chinese Medicine, Chemical Pharmaceutical Technology and Natural Beverages.
Net profit attributable to shareholders dropped 16.70 % to RMB2.10 billion, and total profit fell 15.81 % to RMB2.60 billion, reflecting softer margins, lower government grants and higher finance costs. Earnings per share slipped to RMB1.29 from RMB1.55.
The board proposed an interim cash dividend of RMB0.30 per share, amounting to RMB487.74 million.
Balance-sheet strength remained intact: total assets reached RMB87.82 billion and net assets attributable to shareholders grew 3.56 % to RMB39.13 billion, while the liability-to-asset ratio was broadly stable at 52.76 %. Net operating cash outflow improved to RMB0.27 billion versus a RMB3.40 billion outflow a year earlier.
Strategic and operational highlights included: • R&D portfolio expanded to 160-plus projects, featuring 11 Class 1 innovative drugs—two in phase I trials, four in phase II and one filed for approval. • Marketing reforms and new product launches such as beer-flavoured sparkling herbal tea and plant-protein drinks supported brand building; Wang Lao Ji herbal tea maintained category leadership. • Overseas push advanced with new distribution agreements in Thailand, Indonesia and Uzbekistan, and plant-based beverage localisation partnerships in Europe and Southeast Asia. • Acquisition of 100 % of Zhejiang Pharmaceutical Industry for RMB414.50 million added RMB85.85 million of goodwill. • Continued digital investment saw the AI-driven drug-discovery project selected by China’s Ministry of Industry and Information Technology as a showcase case.
At period end short-term borrowings stood at RMB12.57 billion, long-term borrowings at RMB4.48 billion and outstanding medium-term notes at RMB0.61 billion.
Looking ahead, management will accelerate flagship-product growth, roll out AI-enabled R&D, deepen internationalisation and continue capital-operations to bolster industrial upgrading. The company expects these initiatives to stabilise profitability after first-half pressure on margins.